Clinical Efficacy of CPT-11 Combined with 5-Fu/LV Regimen for Advanced Colorectal Cancer / 中国药房

ABSTRACT

OBJECTIVE: To observe the clinical efficacy and toxic effects of irinotecan (CPT-11) combined with 5-fluorouracil/leucovorin (5-Fu/LV) in the treatment of advanced colorectal cancer. METHODS: Among 31 cases of advanced colorectal cancer, 30 cases were evaluable. All patients received 2 weeks of therapy regimen CPT-11 180 mg?m-2 i.v. gtt d1, LV 200 mg?m-2 i.v. gtt d1～2, 5-Fu 400 mg?m-2 i.v. and 5-Fu 600 mg?m-2 i.v. gtt for 22 h, d1～2. A treatment course last for 14 days. 6 weeks later, clinical efficacy was evaluated. RESULTS: Complete remission was observed in 1 case and partial remission 11 cases. The remission rate (RR) was 40%. Stable disease was reported in 14 cases and disease progression 4 cases. Medium time to progress (TTP) was 6.5 months and medium survival time(MST) was 13.9 months. Major toxic reactions were delayed diarrhea (Ⅲ/Ⅳ grade of 30%) and neutropenia (Ⅲ/Ⅳ grade of 26.6%). CONCLUSION: The regimens of CPT-11 combined with 5-Fu / LV have high response rate and tolerable toxicity in treatment of advanced colorectal cancer. It can be use as first or second line chemotherapy for advanced colorectal cancer.